Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

ing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs.  CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to date to $5 million. The orders are ... . "We continue to see new orders coming ... these orders, our backlog has climbed to over $11 million." ... a leading clean technology company that designs, manufactures and distributes ...
(Date:9/23/2014)... TORONTO , Sept. 23, 2014 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce ... (PPL) has added two more  consultants to its ... uveitis. PPL-003 uses a new proprietary cell permeable ... deliver its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... CAMBRIDGE, Mass. , Sept. 23, 2014   ... developed a comprehensive suite of tools to enable the ... care, today announced that it has been awarded Phase ... Grant (SBIR) from the National Institutes of Health (NIH) ... biorepositories. Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
Breaking Biology Technology:ExakTime Makes Inc. 5000 List for the Fifth Time 2Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... ... biotechnology, ... Sciences today announced a partnership under which,Metahelix will assist in ... expert technological guidance,regarding usage. The efforts of this collaboration will ...
... Market Research, a,global provider of pharmaceutical competitive ... report providing critical strategic insight,for pharma and ... market for Rheumatoid,Arthritis (RA) therapies., In ... Analysis: Rheumatoid,Arthritis Q2 2008, MedPredict,s global Thought ...
... Arete Therapeutics Inc., a,privately-held biopharmaceutical company developing first-in-class ... of,James Sabry, M.D., Ph.D., as president and chief ... and member of the board of directors,since March ... position of,president and chief executive officer, who will ...
Cached Biology Technology:Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences 2Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences 3New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development 2Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer 2
(Date:9/23/2014)... organisms, including humans, have parasitic DNA fragments called "jumping ... instructions in the process. And that phenomenon can result ... the University of Rochester now report that the "jumping ... when a multi-function protein stops keeping them in check ... In a study published today in Nature Communications ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... by-products such as straw could be made quicker and ... UK and France. , Researchers funded by the ... variant straw plants whose cell walls are more easily ... significantly smaller or weaker than regular plants. , ... security as biofuels from non-food crops become easier and ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Reversing the effects of pulmonary fibrosis 2Plant variants point the way to improved biofuel production 2
... protein 'wiring' that differs markedly from the cellular circuitry ... to the development of antimalarial drugs that exploit that ... parasite responsible for an estimated 1 million deaths per ... markedly from the cellular circuitry of other higher organisms, ...
... discovery in basic plant biology that may set the stage ... scientists have identified for the first time a protein that ... toxin to kill the cell. It had been known that ... plant cells, but never before has a protein been found ...
... University have successfully cultured in a laboratory a microorganism with ... advance that may ultimately help shed light on the ecology ... smallest free living cell known and probably the most abundant ... time to study the SAR11 "proteorhodopsin" gene in a laboratory, ...
Cached Biology News:Researchers develop new method to help find deadly malaria parasite's Achilles heel 2Researchers develop new method to help find deadly malaria parasite's Achilles heel 3Biologists discover new pathway into plant cells 2Biologists discover new pathway into plant cells 3Odd energy mechanism in bacteria analyzed 2
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: